Locally advanced rectal cancer: From molecular profiling to clinical practice. A literature review: Part 2

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 15, 2009, Pages 2467-2478

  Berardi, Rossana ^a   Maccaroni, Elena ^a   Onofri, Azzurra ^a   Giampieri, Riccardo ^a   Pistelli, Mirco ^a   Bittoni, Alessandro ^a   Scartozzi, Mario ^a   Pierantoni, Chiara ^a   Mandolesi, Alessandra ^a   Bearzi, Italo ^a   Cascinu, Stefano ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Molecular profiling; Radiochemotherapy; Rectal cancer; Target drugs

Indexed keywords

BEVACIZUMAB; CETUXIMAB; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; K RAS PROTEIN; KI 67 ANTIGEN; OXALIPLATIN; PROTEIN BCL 2; PROTEIN P53; SURVIVIN; THYMIDYLATE SYNTHASE; TRASTUZUMAB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ADJUVANT THERAPY; ADVANCED CANCER; ANGIOGENESIS; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CELL PROLIFERATION; CLINICAL ASSESSMENT; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; COLORECTAL CANCER; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG TARGETING; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; IN SITU HYBRIDIZATION; MICROSATELLITE INSTABILITY; MOLECULAR GENETICS; MULTIMODALITY CANCER THERAPY; ONCOGENE K RAS; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RECTUM BIOPSY; RECTUM CANCER; RECTUM SURGERY; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; TREATMENT FAILURE; TREATMENT PLANNING; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECTAL NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 70349406408     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903143784     Document Type: Review

References (75)

1. Jemal A, Siegel R, Ward E, etal. Cancer statistics, 2008. CA Cancer J Clin 2008;58(2):71-96
2. Glimelius B, Oliveira J. ESMO Guidelines Working Group, Rectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008;19(Suppl 2):ii31-2
3. Kapitejn E, Liefers GJ, Los LC, et al. Mechanism of oncogenesis in colon versus rectal cancer. J Pathol 2001;195:171-178 (Pubitemid 32899025)
4. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-9 •• Preoperative chemoradiotherapy, as compared with postoperative chemoradiotherapy, improved local control and was associated with reduced toxicity but did not improve overall survival. (Pubitemid 39383208)
5. Rodel C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after pre-operative chemoradiotherapy for rectal cancer. J Clin Oncol 2005;23:8688-96 • This study showed that complete (TRG 4) and intermediate pathologic response (TRG 2-3) suggested improved DFS after preoperative CRT in patients with rectal carcinoma. (Pubitemid 46211512)
6. Mohiuddin M, Hayne M, Regine WF, et al. Prognostic significance of post chemoradiation stage following preoperative chemotherapy and radiation for advanced/recurrent rectal cancers. Int J Rad Oncol Biol Phys 2000;48:1075-1080 (Pubitemid 30802145)
7. Sobin LH, Wittekind CH, editors, TNM classification of malignant tumours. Sixth Edition, Wiley-Liss, New York; 2002
8. Compton C, Fenoglio-Preiser CM, Pettigrew N, etal. American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group [review]. Cancer 2000;88(7):1739-1757
9. Royal College of Pathologists (2007) Standards and Dataset for Reporting Cancers: Dataset for colorectal cancer (2nd edition). Available from: http://www.rcpath. org/resources/pdf/G049-ColorectalDataset-Sep07.pdf
10. Baxter NN, Virnig DJ, Rothenberger DA, et al. Lymph node evaluation in colorectal cancer patients: a population-based study. J Natl Cancer Inst 2005;97:219-225 (Pubitemid 40277372)
11. Sarli L, Bader G, Iusco D, etal. Number of lymph nodes examined and prognosis of TNM stage II colorectal cancer. Eur J Cancer 2005;41:272-279
12. Wichmann MW, Muller C, Meyer G, et al. Effect of preoperative radiochemotherapy on lymph node retrieval after resection of rectal cancer. Arch Surg 2002;137:206-210 (Pubitemid 34142139)
13. Marchet A, Mocellin S, Ambrosi A, et al. The ratio between metastatic and examined lymph nodes (N ratio) is an independent prognostic factor in gastric cancer regardless of the type of lymphadenectomy: results from an Italian multicentric study in 1853 patients. Ann Surg 2007;245:543-552
14. Pawlik TM, Gleisner AL, Cameron JL, et al. Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery 2007;141:610-618 (Pubitemid 46616937)
15. Mariette C, Piessen G, Briez N, et al. The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in oesophageal cancer regardless of neoadjuvant chemoradiation or lympadenectomy extent. Ann Surg 2008;247:365-371 (Pubitemid 351156783)
16. Berger AC, Sigurdson ER, LeVoyer T, et al. Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol 2005;23:8706-8712 (Pubitemid 46211514)
17. Stocchi L, Nelson H, Sargent DJ, et al. Impact of surgical and pathologic variables in rectal cancer: a United States community and cooperative group report. J Clin Oncol 2001;19:3895-3902 (Pubitemid 32880068)
18. Kim YS, Kim JH, Yoon SM, etal. lymph node ratio as a prognostic factor in patients with stage III rectal cancer treated with total mesorectal excision followed by chemoradiotherapy. Int J Radiat Oncol Biol Phys 2009;74(3):796-802
19. Rödel C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005;23(34):8688-8696 (Pubitemid 46211512)
20. Bouzourene H, Bosman FT, Seelentag W, et al. Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy. Cancer 2002;94(4):1121-1130 (Pubitemid 34150868)
21. Goldstein NS, Armin M. Epidermal growth factor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 2001;92:1331-1346
22. Yang D, Schneider S, Azuma M, et al. Gene expression levels of epidermal growth factor receptor, survivin, and vascular endothelial growth factor as molecular markers of lymph node involvement in patients with locally advanced rectal cancer. Clin Colorectal Cancer 2006;6(4):305-311 (Pubitemid 46157480)
23. Giralt J, de las Heras M, Cerezo L, et al. The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: a multicenter, retrospective analysis. Radiother Oncol 2005;74(2):101-108
24. Takahari D, Yamada Y, Okita NT, et al. Relationships of insulin-like growth factor-1 receptor and epidermal growth factor receptor expression to clinical outcomes in patients with colorectal cancer. Oncology 2009;76(1):42-48
25. Cunningham MP, Essapen S, Thomas H, et al. Coexpression of the IGF-IR, EGFR and HER-2 is common in colorectal cancer patients. Int J Oncol 2006;28(2):329-335
26. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005;23:1803-1810 (Pubitemid 46211358)
27. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45 •• This randomized PhaseII study demonstrated that cetuximab is able to restore irinotecan sensibility in irinotecan-refractory colorectal cancer. (Pubitemid 38944402)
28. Li C, Gardy R, Seon BK, etal. Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis. Br J Cancer 2003;88(9):1424-1431 (Pubitemid 36606427)
29. Ferrara N, Gerber H-P, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-676
30. Zlobec I, Vuong T, Compton CC, et al. Combined analysis of VEGF and EGFR predicts complete tumour response in rectal cancer treated with preoperative radiotherapy. Br J Cancer 2008;98(2):450-456 (Pubitemid 351161259)
31. Negri FV, Campanini N, Camisa R, et al. Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy. Br J Cancer 2008;98:143-147
32. Giralt J, Navalpotro B, Hermosilla E, et al. Prognostic significance of vascular endothelial growth factor and cyclooxygenase-2 in patients with rectal cancer treated with preoperative radiotherapy. Oncology 2006;71(5-6):312-319
33. Nozue M, Isaka N, Fukao K. Over-expression of vascular endothelial growth factor after preoperative radiation therapy for rectal cancer. Oncol Rep 2001;8:1247-1249 (Pubitemid 33758723)
34. Qiu H, Sirivongs P, Rothenberger M, et al. Molecular prognostic factors in rectal cancer treated by radiation and surgery. Dis Colon Rectum 2000;43:451-459 (Pubitemid 30225425)
35. Noda E, Maeda K, Inoue T, et al. Predictive value of vascular endothelial growth factor-C expression for local recurrence of rectal carcinoma. Oncol Rep 2007;17(6):1327-1331
36. McCormick F. Signal transduction. How receptor turns ras on. Nature 1993;63:15-16
37. Benhattar J, Losi L, Chaubert P, et al. Prognostic significance of K-ras mutations in colorectal carcinoma. Gastroenterology 1993;104:1044-1048 (Pubitemid 23090756)
38. Finkelstein SD, Sayegh R, Bakker A, et al. Determination of tumor aggressiveness in colorectal cancer by K-ras-2 analysis. Arch Surg 1993;128:526-532 (Pubitemid 23143216)
39. Senagore AJ, Thebo-Bienner J. A newly identified pattern of k-ras mutations at codons 12 and 13 is associated with long-term survival in colorectal cancer. Surgery 1997;122:765-770
40. Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 2001;85(5):692-696
41. Bouzourene H, Gervaz P, Cerottini JP, et al. p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer. Eur J Cancer 2000;36:1008-1015 (Pubitemid 30316426)
42. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359(17):1757-65 •• The results of this study showed that patients with a colorectal tumor bearing mutated K-ras did not benefit from cetuximab, whereas patients with a tumor bearing wild-type K-ras did benefit from cetuximab.
43. Van Cutsem E, Lang I, D'haens G, et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience (abstract 2). J Clin Oncol 2008;26(Suppl):5s • The data from this study demonstrated the predictive value of K-ras mutation status for treatment with cetuximab plus FOLFIRI in the first-line treatment of metastatic colorectal cancer: in fact, the treatment effect of cetuximab in patients with K-ras wild-type was significantly enhanced compared with standard chemotherapy alone, whereas patients with mutated K-ras did not receive benefit from cetuximab treatment.
44. Kressner U, Inganäs M, Bydin S, et al. Prognostic value of p53 genetic changes in colorectal cancer. J Clin Oncol 1999;17:593-599 (Pubitemid 29075247)
45. Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 1996;88(20):1442-1455
46. Munro AJ, Lain S, Lane DP. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer 2005;92(3):434-444 (Pubitemid 40395523)
47. Russo A, Bazan V, Iacopetta B, et al.; TP53-CRC Collaborative Study Group. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol 2005;23(30):7518-7528 (Pubitemid 46291815)
48. Jurach MT, Meurer L, Moreira LF. Expression of the p53 protein and clinical and pathologic correlation in adenocarcinoma of the rectum. Arq Gastroenterol 2006;43(1):14-19 (Pubitemid 43735845)
49. Terzi C, Canda AE, Sagol O, et al. Survivin, p53, and Ki-67 as predictors of histopathologic response in locally advanced rectal cancer treated with preoperative chemoradiotherapy. Int J Colorectal Dis 2008;23(1):37-45 (Pubitemid 350142358)
50. Rau B, Sturm I, Lage H, etal. Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy. J Clin Oncol 2003;21(18):3391-3401 (Pubitemid 46594071)
51. Fernebro E, Bendahl PO, Dictor M, et al. Immunohistochemical patterns in rectal cancer: application of tissue microarray with prognostic correlations. Int J Cancer 2004;111(6):921-928 (Pubitemid 39096241)
52. Kim NK, Park JK, Lee KY, etal. p53, BCL-2, and Ki-67 expression according to tumor response after concurrent chemoradiotherapy for advanced rectal cancer. Ann Surg Oncol 2001;8(5):418-424
53. Jakob C, Liersch T, Meyer W, et al. Prognostic value of histologic tumor regression, thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer UICC Stage II/III after neoadjuvant chemoradiotherapy. Am J Surg Pathol 2006;30:1169-1174 (Pubitemid 44299350)
54. Johnston PG, Drake JC, Trepel J, et al. Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res 1992;52:4306-4312
55. Cascinu S, Aschele C, Barni S, et al. Thymidylate Synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil. Clin Cancer Res 1999;5:1996-1999 (Pubitemid 29399249)
56. Popat S, Matakidou A, Houlston RS. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 2004;22:529-536 (Pubitemid 41079782)
57. Liersch T, Langer C, Ghadimi BM, et al. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy. J Clin Oncol 2006;24(25):4062-4068 (Pubitemid 46628475)
58. Bertolini F, Bengala C, Losi L, et al. Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Int J Radiat Oncol Biol Phys 2007;68(5):1455-1461 (Pubitemid 47176800)
59. Calistri D, Presciuttini S, Buonsanti G, et al. Microsatellite instability in colorectal-cancer patients with suspected genetic predisposition. Int J Cancer 2000;89:87-91 (Pubitemid 30078755)
60. Hemminki A, Mecklin JP, Jarvinen H, et al. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology 2000;119:921-928 (Pubitemid 30777912)
61. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis [review]. J Clin Oncol 2005;23(3):609-618 (Pubitemid 46224239)
62. Malesci A, Laghi L, Bianchi P, et al. Reduced likelihood of metastases in patients with microsatellite-unstable colorectal cancer. Clin Cancer Res 2007;13(13):3831-3839 (Pubitemid 47037588)
63. Meng WJ, Sun XF, Tian C, et al. Microsatellite instability did not predict individual survival in sporadic stage II and III rectal cancer patients. Oncology 2007;72(1-2):82-88 (Pubitemid 350249134)
64. Carethers JM, Smith EJ, Behling CA, et al. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology 2004;126(2):394-401 (Pubitemid 38182296)
65. Storojeva I, Boulay JL, Heinimann K, et al. Prognostic and predictive relevance of microsatellite instability in colorectal cancer. Oncol Rep 2005;14(1):241-249 (Pubitemid 41158983)
66. Que FG, Gores GJ. Cell death by apoptosis: basic concepts and disease relevance for the gastroenterologist. Gastroenterology 1996;110:1238-1243 (Pubitemid 26113764)
67. Bhatavdekar JM, Patel DD, Ghosh N, et al. Coexpression of bcl-2, c-myc and p53 oncoproteins as prognostic discriminants in patients with colorectal carcinoma. Dis Colon Rectum 1997;40:785-790 (Pubitemid 27295049)
68. Schwandner O, Schieck THK, Bruch HP, et al. p53 and bcl-2 as significant predictors of recurrence and survival in rectal cancer. Eur J Cancer 2000;36:348-356 (Pubitemid 30116731)
69. Sarela AI, Scott N, Ramsdale J, et al. Immunohistochemical detection of the anti-apoptosis protein, survivin, predicts survival after curative resection of stage II colorectal carcinomas. Ann Surg Oncol 2001;8:305-310 (Pubitemid 32422855)
70. Kawasaki H, Altieri DC, Lu CD, et al. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 1998;58:5071-5074 (Pubitemid 28521163)
71. Rödel F, Hoffmann J, Distel L, et al. Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 2005;65(11):4881-4887 (Pubitemid 40740827)
72. Kapahi P, Takahashi T, Natoli G, et al. Inhibition of NFkappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase. J Biol Chem 2000;275:36062-36066 (Pubitemid 30841151)
73. Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 2003;114:181-190 (Pubitemid 36936912)
74. Scartozzi M, Bearzi I, Pierantoni C, et al. Nuclear factor-κB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy. J Clin Oncol 2007;25(25):3930-3935 (Pubitemid 47477270)
75. Cascinu S, Berardi R, Salvagni S, et al. A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-κB activation. Br J Cancer 2008;98(1):71-76